ENLIVEN THERAPEUTICS, INC. Temporary Equity, Liquidation Preference
ENLIVEN THERAPEUTICS, INC. (ELVN) had Temporary Equity, Liquidation Preference of $80.06 million as of 2019-12-31, per its 10-K filed 2021-03-05.
Discontinued › Balance Sheet › Temporary Equity › Temporary Equity, Other Disclosure
us-gaap:TemporaryEquityLiquidationPreference · last filed 2021-03-05
- 2019-12-31: Temporary Equity, Liquidation Preference $80.06M.
| Period end | Temporary Equity, Liquidation Preference |
|---|---|
| 2019-12-31 | $80.06M 10-K · filed 2021-03-05 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Arcutis Biotherapeutics, Inc. (ARQT) | United States | $3.303B | 115.47 |
| Amylyx Pharmaceuticals, Inc. (AMLX) | United States | $3.361B | -13.15 |
| Arcus Biosciences, Inc. (RCUS) | United States | $3.188B | -8.52 |
| Dyne Therapeutics, Inc. (DYN) | United States | $3.084B | -7.09 |
| IDEAYA Biosciences, Inc. (IDYA) | United States | $3.540B | -20.52 |
| Organon & Co. (OGN) | United States | $3.603B | 17.03 |
| Xenon Pharmaceuticals Inc. (XENE) | $3.684B | -14.27 | |
| ACADIA PHARMACEUTICALS INC (ACAD) | United States | $3.823B | 11.45 |
| PRECIGEN, INC. (PGEN) | United States | $2.757B | -12.94 |
| AbCellera Biologics Inc. (ABCL) | $3.879B | -14.59 |